Found: 28
Select item for more details and to access through your institution.
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, p. 1, doi. 10.1177/20552173211024298
- By:
- Publication type:
- Article
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, v. 7, n. 3, p. 1, doi. 10.1177/20552173211024298
- By:
- Publication type:
- Article
Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, v. 7, n. 1, p. 1, doi. 10.1177/2055217321990852
- By:
- Publication type:
- Article
Clinical -- Magnetic Resonance Imaging Correlations in Multiple Sclerosis.
- Published in:
- Journal of Neuroimaging, 2005, v. 15, p. 10S, doi. 10.1177/1051228405283291
- By:
- Publication type:
- Article
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.763433
- By:
- Publication type:
- Article
CD45 (PTPRC) as a candidate gene in multiple sclerosis.
- Published in:
- Multiple Sclerosis (13524585), 2004, v. 10, n. 6, p. 614, doi. 10.1191/1352458504ms1115oa
- By:
- Publication type:
- Article
Resistance to a non-immunogenic tumor, induced by Corynebacterium parvum or Listeria monocytogenes, is abrogated by anti-interferonγ.
- Published in:
- International Journal of Cancer, 1990, v. 46, n. 4, p. 687, doi. 10.1002/ijc.2910460423
- By:
- Publication type:
- Article
Increased Activated Human T Cell Lymphotropic Virus Type I (HTLV-I) Tax11-19-Specific Memory and Effector CD8[superscript +] Cells in Patients with HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: Correlation with HTLV-I Provirus Load.
- Published in:
- Journal of Infectious Diseases, 2001, v. 183, n. 2, p. 197, doi. 10.1086/317932
- By:
- Publication type:
- Article
HTLV-I/II Seroindeterminate Western Blot Reactivity in a Cohort of Patients with Neurological...
- Published in:
- Journal of Infectious Diseases, 1999, v. 180, n. 3, p. 685, doi. 10.1086/314923
- By:
- Publication type:
- Article
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 790, doi. 10.1177/13524585211035740
- By:
- Publication type:
- Article
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
- Published in:
- Drugs, 2020, v. 80, n. 18, p. 1901, doi. 10.1007/s40265-020-01422-9
- By:
- Publication type:
- Article
Toward a practical protocol for human optic nerve DTI with EPI geometric distortion correction.
- Published in:
- Journal of Magnetic Resonance Imaging, 2009, v. 30, n. 4, p. 699, doi. 10.1002/jmri.21836
- By:
- Publication type:
- Article
Association of haplotypes in theß-chemokine locus with multiple sclerosis.
- Published in:
- European Journal of Human Genetics, 2005, v. 13, n. 2, p. 240, doi. 10.1038/sj.ejhg.5201295
- By:
- Publication type:
- Article
Involvement of β-chemokines in the development of inflammatory demyelination.
- Published in:
- Journal of Neuroinflammation, 2005, v. 2, p. 7, doi. 10.1186/1742-2094-2-7
- By:
- Publication type:
- Article
Interferon‐β1a therapy in human T‐lymphotropic virus type I–associated neurologic disease.
- Published in:
- Annals of Neurology, 2005, v. 57, n. 4, p. 526
- By:
- Publication type:
- Article
N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study.
- Published in:
- Frontiers in Neurology, 2020, v. 11, p. 1, doi. 10.3389/fneur.2020.00088
- By:
- Publication type:
- Article
(DXT74) An Analysis of the Relationship Between Cladribine Dose and Risk of Malignancies in Patients with Multiple Sclerosis.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 42
- By:
- Publication type:
- Article
(DXT73) Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Postapproval Data.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 42
- By:
- Publication type:
- Article
(DXT34) Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine-Treated Patients at the 96-Week Timepoint (CLARITY) Using Deconvolution Algorithms.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 27
- By:
- Publication type:
- Article
(DXT42) Rationale and Design of CLASSIC-MS Study Evaluating Long-Term Efficacy for Patients with Multiple Sclerosis Treated with Cladribine Tablets.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 30
- By:
- Publication type:
- Article
(DXT27) Integrated Lymphopenia Analysis in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 25
- By:
- Publication type:
- Article
(DXT22) Characterization of Incidence and Time-to-Recovery from Grade 3/4 Lymphopenia Lasting =6 Months in Patients with Multiple Sclerosis Treated with Cladribine Tablets.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 23
- By:
- Publication type:
- Article
(DMT04) Treatment-Emergent Adverse Events Occurring Early in the Treatment Course of Cladribine Tablets in Two Phase 3 Trials in Multiple Sclerosis.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 5
- By:
- Publication type:
- Article
T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 6, p. 648, doi. 10.1177/13524585221134216
- By:
- Publication type:
- Article
Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients.
- Published in:
- Annals of Neurology, 2000, v. 47, n. 3, p. 306, doi. 10.1002/1531-8249(200003)47:3<306::AID-ANA5>3.0.CO;2-A
- By:
- Publication type:
- Article
Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-tac.
- Published in:
- Annals of Neurology, 1998, v. 44, n. 6, p. 942, doi. 10.1002/ana.410440613
- By:
- Publication type:
- Article
On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases.
- Published in:
- European Journal of Immunology, 1989, v. 19, n. 4, p. 689, doi. 10.1002/eji.1830190418
- By:
- Publication type:
- Article
Increased bactericidal macrophage activity induced by immunological stimuli is dependent on interferon (IFN)-Γ.
- Published in:
- European Journal of Immunology, 1988, v. 18, n. 8, p. 1295, doi. 10.1002/eji.1830180822
- By:
- Publication type:
- Article